GSK agreed to acquire Canada-based 35Pharma Inc. for $950 million to expand its pulmonary hypertension pipeline with HS235, an investigational medicine targeting the activin receptor signalling pathway. The acquisition comes as GSK also signed a licensing deal with Frontier Biotechnologies and previously agreed to acquire RAPT Therapeutics for $2.2 billion, strengthening its position in the growing PH therapeutics market projected to reach $18 billion by 2032.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.

Monteverde & Associates PC is investigating four merger and acquisition transactions involving RAPT Therapeutics, Amicus Therapeutics, Tamboran Resources, and Contango Ore. The firm is encouraging shareholders to act before upcoming votes and tender offer deadlines in March 2026, citing concerns about the proposed deals.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.

Rapt Therapeutics shares surged 64% after British pharmaceutical giant GSK agreed to acquire the biotech company for $2.2 billion, or $58 per share. The deal grants GSK global rights to ozureprubart, Rapt's experimental antibody therapy currently in phase 2 trials designed to treat severe food allergies affecting over 1.3 million people in the U.S.

Monteverde & Associates PC, a class action securities firm, has announced an investigation into RAPT Therapeutics' proposed acquisition by GSK plc. Under the deal terms, RAPT shareholders are expected to receive $58.00 per share in cash. The firm is investigating whether the transaction represents a fair deal for shareholders.

GSK has agreed to acquire RAPT Therapeutics for $2.2 billion, marking the second exit for Forbion Growth Fund III. RAPT's lead candidate ozureprubart is a long-acting monoclonal antibody for severe allergic diseases currently in late-stage clinical development. The transaction is expected to close in Q1 2026.

GSK agreed to acquire RAPT Therapeutics for $58.00 per share ($2.2 billion equity value) to gain ozureprubart, a long-acting anti-IgE monoclonal antibody in phase 2b development for food allergy protection. The drug offers potential quarterly dosing versus current bi-weekly injections. Concurrently, Pfizer is exiting its 11.7% stake in ViiV Healthcare for $1.875 billion, with Shionogi increasing its holding to 21.7%.

The food allergy market is expected to grow significantly by 2034, driven by emerging therapies, increased diagnoses, and rising treatment costs. The market was valued at USD 3 billion in 2024, with the US accounting for approximately 79% of the total market.

RAPT Therapeutics plans to raise approximately $250 million through a public offering of 8,333,334 common stock shares at $30.00 per share, with potential additional shares through underwriters' option.

RAPT Therapeutics plans to report topline data from a Phase 2 clinical trial of RPT904 for Chronic Spontaneous Urticaria, conducted with partner Shanghai Jeyou Pharmaceutical, on October 20, 2025.